Latest Breaking News On - Lavoie health science - Page 9 : comparemela.com

Press release content from Globe Newswire. The AP news staff was not involved in its creation. AC Immune’s Alzheimer’s Vaccine Generates Potent Anti-pTau Antibody Response in a Phase 1b/2a Study AC Immune SAFebruary 11, 2021 GMT Interim results of ACI-35.030 vaccination show high titers of antigen-specific antibodies at potentially therapeutic levels in 100% of older patients with early Alzheimer’s disease ACI-35.030 was safe and well tolerated with no safety concerns observed. Results support plans to further develop the Alzheimer’s vaccine into Phase 2/3 LAUSANNE, Switzerland, Feb. 11, 2021 (GLOBE NEWSWIRE) AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced positive interim results from its ongoing Phase 1b/2a clinical trial evaluating its first-in-class anti-phospho-Tau (pTau) vaccine candidate ACI-35.030 for the treatment of Alzheimer’s disease (AD). ACI

Chris maggosAndrea pfeiferKatie gallagherEli lillyJoshua drummLavoie health scienceJanssen pharmaceuticals incExchange commissionSecurities exchangeRoche groupJanssen pharmaceuticalsTau iggTau igmInvestor relationsSecurities actSecurities exchange act